Moderna Inc. ($MRNA) Stock Forecast: Up 5.6% Today

What is Moderna Inc.?

Merck & Co., Inc. (MRK) Bullish Market Movement

Why is Moderna Inc. going up?

MRNA stock is up 5.6% on Feb 19, 2026 18:36

• Merck & Co., Inc. (MRK) is a pharmaceutical company recognized for its innovative healthcare solutions. Today, the stock saw significant bullish movement in the market.
• MRK upgraded to a Buy rating by Deutsche Bank with a higher price target, noting undervaluation despite Keytruda patent cliff concerns.
• FDA approval of KEYTRUDA® and KEYTRUDA QLEX™ for a new indication strengthened investor confidence in the company's growth prospects.
• Positive developments regarding MRK outshined worries about the Keytruda patent cliff, leading to the stock's bullish market movement.
• Investor optimism towards MRK's future growth prospects and product portfolio expansion drove the market's positive reaction.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Where is Pfizer Inc. (PFE) Headed?

Pfizer Inc. (PFE) faces a downgrade to Neutral from Daiwa with a $27 price target, yet received Priority Review from the FDA for its HYMPAVZI® sBLA, aiming to expand its approved indication for hemophilia treatment. Despite these developments, the article suggests that certain AI stocks might offer greater upside potential with less risk than PFE.

https://finviz.com/news/315800/where-is-pfizer-inc-pfe-headed

Where is Merck & Co., Inc. (MRK) Headed According to the Street?

Merck & Co., Inc. (MRK) has been upgraded to a Buy rating by Deutsche Bank with a raised price target due to belief that the market undervalues the company despite the looming Keytruda patent cliff. The firm sees a clear path for the company's growth, excluding Keytruda. Additionally, the FDA approved KEYTRUDA® and KEYTRUDA QLEX™ for treating platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma with specific PD-L1+ characteristics, marking them as the first and only PD-1 inhibitors for this indication.

https://finviz.com/news/315797/where-is-merck-co-inc-mrk-headed-according-to-the-street

Truist Securities Cuts IQVIA Price Target to $245 From $290, Maintains Buy Rating

Truist Securities has lowered its price target for IQVIA Holdings Inc. (IQV) to $245 from $290, while reiterating a Buy rating on the stock. This adjustment comes despite competitor Charles River forecasting an upbeat 2026 profit due to improved demand for drug development services. Other analysts, including TD Cowen, UBS, Leerink Partners, and Evercore ISI, have also recently adjusted their price targets for IQVIA.

https://www.marketscreener.com/news/truist-securities-cuts-iqvia-price-target-to-245-from-290-maintains-buy-rating-ce7e5ddcda80f027

BioNTech vaccine update: what US patients should really know now

This article provides an update on the BioNTech/Pfizer COVID vaccine for US patients in 2026, focusing on its transition from an emergency pandemic tool to a seasonal-style protection product. It covers what's new, including updated formulations targeting current variants, clearer safety profiles, and flexible booster schedules, while addressing real-world availability, cost, and expert recommendations based on age and risk groups. The piece emphasizes the vaccine's continued effectiveness in preventing severe disease, hospitalization, and death, particularly for high-risk individuals, despite waning protection against mild infection.

https://www.ad-hoc-news.de/boerse/news/ueberblick/biontech-vaccine-update-what-us-patients-should-really-know-now/68591702

FDA reverses course and will review Moderna’s mRNA flu shot, company says

Moderna announced that the FDA has reversed its initial refusal and will now review the company's new mRNA seasonal flu vaccine. The FDA had initially rejected Moderna's application due to concerns about the control arm of its trial. Moderna has since proposed a revised regulatory approach, seeking full approval for adults aged 50-64 and accelerated approval for those 65 and older, with a potential launch for the 2026-2027 flu season.

https://www.wcvb.com/article/moderna-mrna-flu-fda-review-2026/70405348

Trending Today

Teladoc Health Inc. ($TDOC) Stock Forecast: Up 5.6% Today

Tilray Inc. ($TLRY) Stock Forecast: Up 5.8% Today

Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Up 6.3% Today

SolarEdge Technologies, Inc. ($SEDG) Stock Forecast: Up 7.9% Today

DENTSPLY SIRONA Inc. ($XRAY) Stock Forecast: Down 6.4% Today

FuelCell Energy ($FCEL) Stock Forecast: Up 5.9% Today

Shoals Technologies Group Inc. ($SHLS) Stock Forecast: Down 5.4% Today

Wingstop Inc. ($WING) Stock Forecast: Down 6.8% Today

Delta Air Lines Inc. ($DAL) Stock Forecast: Down 5.1% Today

United Continental Holdings Inc. ($UAL) Stock Forecast: Down 5.3% Today

Moderna Inc. Price History

11.01.2026 - MRNA Stock was down 9.3%

• A recent FDA decision on Moderna's flu vaccine application is seen as a setback for the company's vaccine pipeline, potentially influencing the bearish movement in the stock.
• However, the acceptance of mRNA-1010 for review in various regions such as the EU, Canada, and Australia may offer some comfort to investors, mitigating the overall impact on Moderna's financial prospects.
• The company's new five-year vaccine agreement with the Mexican government has the potential to counterbalance the negative sentiment from the FDA decision, indicating a strategic move for revenue growth and expansion into new markets.
• The market's response to Moderna's bearish trend today may reflect the varied reports on its vaccine developments and collaborations, with investors keen on monitoring the firm's regulatory advancements and commercial ventures in the future.

11.01.2026 - MRNA Stock was down 15.2%

• The FDA rejection of Moderna's flu vaccine application likely contributed to the bearish movement in MRNA stock. This setback could have raised concerns among investors about the company's pipeline and future revenue streams.
• Despite the FDA rejection, Moderna's strategic agreements with the Mexican government and local pharmaceutical companies could provide a potential revenue boost in the long term. However, the immediate market reaction seems to have been overshadowed by the negative news of the flu vaccine application rejection.
• The news of Moderna's acceptance for review in other regions like the EU, Canada, and Australia might have mitigated some of the stock's losses, indicating potential global market opportunities for the company.
• Overall, the market movement in MRNA today reflects a mix of regulatory challenges and strategic partnerships, showcasing the volatility and resilience of the biopharmaceutical sector.

19.01.2026 - MRNA Stock was up 5.6%

• Merck & Co., Inc. (MRK) is a pharmaceutical company recognized for its innovative healthcare solutions. Today, the stock saw significant bullish movement in the market.
• MRK upgraded to a Buy rating by Deutsche Bank with a higher price target, noting undervaluation despite Keytruda patent cliff concerns.
• FDA approval of KEYTRUDA® and KEYTRUDA QLEX™ for a new indication strengthened investor confidence in the company's growth prospects.
• Positive developments regarding MRK outshined worries about the Keytruda patent cliff, leading to the stock's bullish market movement.
• Investor optimism towards MRK's future growth prospects and product portfolio expansion drove the market's positive reaction.

18.01.2026 - MRNA Stock was up 9.5%

• Moderna faced setbacks in a patent dispute with Arbutus Biopharma, but the market remained bullish, indicating that investors are focusing more on the company's overall potential and developments in its vaccine pipeline.
• The FDA's decision to review Moderna's mRNA flu shot application, along with the positive results from the mid-stage trial of their combo flu/COVID vaccine, likely contributed to the bullish movement of the stock.
• Despite the ongoing legal challenges and regulatory hurdles, Moderna's innovative approach to vaccine development and the promising results of its trials seem to have instilled confidence in investors, driving the stock price up.

18.01.2026 - MRNA Stock was up 5.5%

• Optimism among investors was ignited by the FDA's decision to reassess Moderna's mRNA flu shot application after an initial rejection, potentially creating a new revenue source for the company.
• Despite uncertainties stemming from setbacks in the patent dispute with Arbutus Biopharma, investor focus on the flu vaccine review seemed to outweigh these concerns.
• Strong results from Moderna's combination flu/COVID vaccine trial further solidified investor confidence in the company's capabilities and future outlook, driving the bullish movement in stock price.
• Overall, market response to the FDA's review of Moderna's flu shot and encouraging vaccine trial outcomes indicates investor optimism about the company's ongoing success and innovation within the healthcare sector.

06.01.2026 - MRNA Stock was down 6.1%

• The stock experienced a bearish movement, possibly due to the anticipation of its upcoming quarterly earnings projecting a loss per share and lower revenue than expected.
• Recent insider selling activity might have also contributed to the negative sentiment surrounding the stock.
• The launch of leveraged ETFs tied to the company's share prices could have amplified the downward pressure on the stock as traders adjusted their positions based on market volatility and risk factors associated with leveraged products.

10.01.2026 - MRNA Stock was up 8.9%

• Today, Moderna's positive stock movement is linked to the favorable investor sentiment surrounding its advancements in cancer vaccine development and its overall market success.
• A strategic partnership with Mexico to bolster vaccine manufacturing capacity and provide respiratory vaccines has likely instilled confidence in investors regarding Moderna's growth prospects.
• Endorsement by Jim Cramer as a top-performing stock of the year has also bolstered Moderna's positive momentum, showcasing its resilience and future potential.
• Projected revenue growth in 2026 and ongoing research and development endeavors by key players in the biotechnology sector, including Moderna, point towards a promising outlook for the company's future performance.

10.01.2026 - MRNA Stock was up 5.4%

• Moderna's positive performance today is linked to the strategic agreement reached with Mexico, which not only strengthens its global presence but also augments its revenue potential.
• Despite initial concerns stemming from a Sell rating and low price target by Bank of America Securities, news of the partnership with Mexico overshadowed these sentiments, boosting investor confidence.
• Collaborations such as the one with Recordati to advance investigational therapeutics highlight Moderna's diversification efforts beyond COVID-19 vaccines, further bolstering its long-term growth outlook.
• The overall optimistic trend in the biotechnology sector, especially within the United States market poised for significant advancements, likely contributed to the favorable stance on Moderna's stock today.

10.01.2026 - MRNA Stock was up 5.4%

• Moderna saw a surge in its stock value today due to recent strategic partnerships and agreements with the Mexican government. These initiatives aim to expand geographically, bolster local vaccine production, and fortify its position in global markets.
• The favorable reception from investors towards Moderna, acknowledged by notable market analysts, has also contributed to its upward movement as one of the standout stocks presently. Investor enthusiasm is fueled by Moderna's growth trajectory and promising ventures in cancer vaccines.
• Market response indicates a strong belief in Moderna's future revenue growth forecasts and its dedication to improving pandemic readiness and public health responses, exemplified by collaborations such as the one with Mexico.
• In essence, Moderna's positive market performance today reflects a blend of well-thought-out business strategies and optimistic market sentiment towards the company's expansion plans and groundbreaking vaccine technologies.

12.01.2026 - MRNA Stock was up 8.6%

• Moderna's stock experienced a strong bullish movement following the news of a five-year agreement with Mexico to enhance mRNA vaccine supply for respiratory diseases. This collaboration not only expands Moderna's market reach but also signifies its commitment to global health initiatives.
• The FDA's rejection of Moderna's flu vaccine application might have initially caused some uncertainty in the market. However, the positive development with Mexico and the focus on respiratory vaccines could have overshadowed this setback, driving the bullish momentum.
• The market seems to be reacting favorably to Moderna's strategic partnerships and long-term growth prospects, positioning the company as a key player in the biotech industry. Investors are likely viewing Moderna as a solid investment choice amidst ongoing advancements in medical technology and global health priorities.

13.01.2026 - MRNA Stock was up 7.3%

• Moderna experienced a strong bullish movement today as its sales beat expectations, driven by robust demand for its Covid-19 vaccine, which declined less than anticipated.
• The positive sales performance indicates that Moderna continues to play a significant role in the global vaccination efforts, contributing to its revenue growth.
• The market's reaction to Moderna's sales beat showcases investor confidence in the company's ability to navigate through changing demand dynamics for Covid-19 vaccines.
• The news of Moderna's sales exceeding estimates likely fueled investor optimism and contributed to the bullish movement in the stock price.

13.01.2026 - MRNA Stock was up 6.7%

• Moderna's stock experienced a bullish movement as the company exceeded fourth-quarter revenue expectations, driven by better-than-expected sales of its Covid vaccine.
• The positive outlook for Moderna can also be attributed to the overall market sentiment, with U.S. consumer prices rising less than anticipated, providing a boost to investor confidence.
• The increased capital injection into Jiuzi Holdings by multiple crypto investment institutions may have also contributed to a positive market sentiment, indirectly benefiting Moderna and other companies in the market.
• Analysts closely monitoring Moderna's performance amidst competition in the biotech space, particularly in the kidney disease portfolio and the expanding applications of its drugs, could have further fueled investor optimism in the stock.